4-异喹啉甲酸 | 7159-36-6

• 物质功能分类: 医药中间体 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 4-异喹啉甲酸
• 中文别名: 异喹啉-4-羧酸；异喹啉-4-甲酸
• 英文名称: isoquinoline-4-carboxylic acid
• 英文别名: 4-isoquinolinecarboxylic acid；isoquinolin-4-carboxylic acid
• CAS: 7159-36-6
• 化学式: C₁₀H₇NO₂
• 分子量: 173.171
• InChiKey: MCVMLYSLPCECGO-UHFFFAOYSA-N

物化性质

• 熔点：
  264-266 °C
• 沸点：
  405.6±18.0 °C(Predicted)
• 密度：
  1.339±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R22,R36
• 海关编码：
  2933499090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Isoquinoline-4-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: Isoquinoline-4-carboxylic acid
CAS number: 7159-36-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H7NO2
Molecular weight: 173.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-异喹啉甲酸 在 氯化亚砜 作用下， 生成 异喹啉-4-甲酸甲酯
  参考文献：
  名称：

  Synthesis of Isoquinoline Acids

  摘要：

  DOI：

  10.1021/ja01870a059
• 作为产物：
  描述：

  3-溴异喹啉 在 四(三苯基膦)钯 、 水 、 potassium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-异喹啉甲酸
  参考文献：
  名称：

  CANNABINOID RECEPTOR MODULATORS

  摘要：

  公式（I）的化合物以及用于制备这些化合物的方法，可用于治疗、管理和/或减轻与大麻素（CB）受体调节相关的疾病、紊乱、综合症或症状。治疗、管理和/或减轻与公式（I）的大麻素（CB）受体调节相关的疾病、紊乱、综合症或症状的方法。

  公开号：

  US20130178457A1

文献信息

• 1, 2-Dihydroisoquinoline-N-acetic Acid Derivatives as New Carriers for Brain-specific Delivery II: Delivery of Phenethylamine as Model Drug
  作者：Sahar Mahmoud、Mahmoud Sheha、Tarek Aboul-Fadl、Hassan Farag

  DOI：10.1002/ardp.200300764

  日期：2003.7

  N‐alkyloxycarbonylmethyl‐1, 2‐dihydroisoquinolin‐4‐carboxylic acid derivatives 7a‐c synthesized as new carriers for brain specific delivery. The design of the carrier systems are based on sequential hydrolysis at the acetic acid ester group linked to dihydroisoquinoline nitrogen followed by ring oxidation and formation of quaternary isoquinolinium derivatives which are then hydrolyzed to release the drug. Once the

  N-烷氧基羰基甲基-1, 2-二氢异喹啉-4-羧酸衍生物7a-c合成为大脑特异性递送的新载体。载体系统的设计基于与二氢异喹啉氮相连的乙酸酯基团的顺序水解，然后环氧化并形成季异喹啉衍生物，然后水解释放药物。一旦载体系统被施用，将发生连续的酶促过程，导致其氧化速率显着增加，这是大脑特异性递送的关键因素。在水性缓冲溶液和铁氰化物试剂中研究了合成载体系统的化学稳定性，并证明在配制和储存过程中对水合和氧化非常稳定。此外，还在 80% 的人血浆和 20% 的兔脑匀浆中研究了酶的稳定性。发现氧化和水解都发生了；然而，水解是主要途径。在大鼠中研究的乙酯衍生物 7b 的体内分布表明，季产物的浓度在大脑中增加并随着时间从血液中清除。
• SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS
  申请人：COATE Heather R.

  公开号：US20160046640A1

  公开（公告）日：2016-02-18

  The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphihalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyi, tlisazolyl, isoxazolvl, pyrazolyl, imidazothiazolyi, benzimidazolyl, or indazolyi; R 1 is H, alky], aikoxy, hydroxyalkylene, OH, halo, phenyl, triazolyl, oxazolyl, isoxazofyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, piperazinyl, pyrazolyl, oxadiazolvl, pyrrolidinyl, thiophenyi, morpholinyl, or dialkyiamino; R 2 is H, alkyl, aikoxy, hydroxyalkylene, or halo; Z is NH, N-alkyl, or O; R 5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, qumazolinyi, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, aikoxy, or halo; and n is 0 or 1, Methods of making the compounds of Formula 1 are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：其中环A为苯基、萘基、吡啶基、喹啉基、异喹啉基、咪唑吡啉基、呋喃基、噻唑基、异噁唑基、吡唑基、咪唑噻唑基、苯并咪唑基或吲哚基；R1为H、烷基、烷氧基、羟基烷基、OH、卤素、苯基、三唑基、噁唑基、异噁唑基、吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、哌嗪基、吡唑基、噁二唑基、吡咯烷基、噻吩基、吗啉基或二烷氨基；R2为H、烷基、烷氧基、羟基烷基或卤素；Z为NH、N-烷基或O；R5为吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、喹唑啉基、喹喹啉基、吡唑基、苯并噁唑基、咪唑吡嗪基、三唑咪唑基，可选地取代一个或两个独立选择自烷基、烷氧基或卤素的基团；n为0或1，还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的药物组合物。本发明还涉及使用该化合物的方法。
• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20200102303A1

  公开（公告）日：2020-04-02

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.

  化合物的结构式（I）和结构式（II），含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、紊乱和病况的方法，例如与疼痛、精神障碍、神经障碍（包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、躁郁症）、癌症和眼部疾病相关的方法。 其中R1、R2、R2a、R3、R3a、R4和R4a在此处定义。
• [EN] SYNTHESIS OF DEUTERATED ALDEHYDES<br/>[FR] SYNTHÈSE D'ALDÉHYDES DEUTÉRÉS
  申请人：UNIV ARIZONA

  公开号：WO2021045879A1

  公开（公告）日：2021-03-11

  Described are methods for preparing a deuterated aldehyde using N-heterocyclic carbene catalysts in a solvent comprising D2O. The methods may be used to convert a wide variety of aldehydes (e.g., aryl, alkyl, or alkenyl aldehydes) to C-1 deuterated aldehydes under mild reaction conditions without functionality manipulation.

  描述了使用包含重水(D2O)的溶剂中的N-杂环卡宾催化剂来制备氘代乙醛的方法。这些方法可以在温和的反应条件下，不改变功能团的情况下，将各种乙醛（例如，芳香醛、脂肪醛或不饱和脂肪醛）转化为C-1位置氘代的乙醛。
• 喹啉酰胺类化合物的制备方法
  申请人：河南农业大学

  公开号：CN111995575A

  公开（公告）日：2020-11-27

  本发明属于有机合成技术领域，具体公开了一种喹啉酰胺类化合物的制备方法，包括下列步骤：（1）将喹啉羧酸类化合物和秋兰姆加入有机溶剂中进行反应，得到反应液；（2）将步骤（1）所得反应液进行分离纯化，即得。本发明采用一锅煮的方法，以经济易得的喹啉羧酸类化合物和秋兰姆为原料，在空气中直接发生酰胺化反应生成相应的喹啉酰胺类化合物。本发明合成体系适用范围较广，兼容喹啉基和酰胺基等官能团，工艺简单，操作方便，反应条件温和，底物范围较广，具有较高的产率，适合推广应用。

表征谱图